Protara Therapeutics Inc. (TARA) is a clinical-stage biopharmaceutical enterprise dedicated to identifying, developing, and commercializing transformative new therapies for the treatment of cancer and rare, life-threatening conditions with high unmet medical needs. Investing in the stock provides exposure to the volatile biotechnology sector, where corporate value is driven primarily by successful clinical trial milestones, regulatory approvals, and the eventual commercialization of proprietary medical treatments.